Contact

ANACONDA BIOMED: MEDICAL TECHNOLOGY


, ,
Integral service around a transaction
BY : Diego GutiérrezDecember Tue, 2019

Anaconda Biomed es una Startup española, con sede en Barcelona, que desarrolla un catéter de nueva generación para tratar de manera eficiente el ictus.

Recientemente, ha sold parte de su accionariado por 20M€.

This makes the deal the second largest in the health sciences sector so far this year.

Medical technology is so important, and so much in the news, that it continues to attract private capital.

Both the sector and its movements in corporate finance give a good account of this.

WHO IS ANACONDA BIOMED?

Anaconda Biomed is one of the world's most innovative medical technology companiesfounded in 2015.

It is currently developing ANCD BRAIN.

It is a novel system of mechanical thrombectomy with catheter used to treat acute ischemic stroke, also known as acute ischemic stroke, also known as acute ischemic stroke. Ictus.

This catheter allows the thrombus causing it to be captured and aspirated.

The system is introduced into the artery, and is able to suspend blood flow and capture the trophoblast.mbo without residues remaining in the patient's circulation.

SECOND MOST IMPORTANT OPERATION

At the beginning of December, sold part of its shares in the company.

It has done so in a round amounting to 20M€making it the second largest deal in the healthcare sector in 2019.

La primera fue los 72M€ que se invirtieron el pasado mes de junio en Sanifit Therapeutics.

But as far as the sale that is the subject of this post is concerned, all the investors who had already participated in the previous sale have participated.

Algunos de ellos son, por ejemplo, Ysios Capital, Banco Sabadell, Innogest y Omega Funds.

Since its launch, Anaconda Biomed has already raised €40 million.

PRODUCT VALIDATION IN EUROPE AND THE U.S.A.

The €20 million will be used by the firm for a clinical study to validate its product in both the European Medicines Agency (EMA), as in the American Food Drug Administration (FDA).

In total, 125 patients will be recruited, with results expected by the end of the third quarter of next year.

But it's not all plain sailing for the company.

The entry into force of the new medical device regulation in Europe has forced them to change their strategy: more patients in clinical trials and more investment are needed.

MARKET LAUNCH IN 2021

If approved, the new release date is early 2021.

At this point, it is worth noting that in the medical device market, it is common for companies to take the first steps towards commercialisation, followed by licensing or purchase agreements.

Entre las multinacionales más interesadas en este área médica, se encuentran Medtronic, Johnson & Johnson y Stryker, entre otros.

THROMBECTOMIES AND STROKES

The mechanical thrombectomy market accounted for $720M in revenues in the US last year.

Although it should be taken into account that it is a sector that has been indicated since 2015, and previously it was not included in the medical guidelines.

The Ictus is the leading cause of disability and the second leading cause of death in the world.

OTHER RELEVANT INDUSTRY ROUNDS

PSIOUS

Psious develops virtual reality platform designed to add value to mental health treatment.

It uses hyper-realistic virtual environments to treat anxiety disorders through virtual exposure therapy.

In this way, professionals can improve mental health therapies.

Recently, the company has sold part of its shareholding for 8M€ for their growth.

TAAP WATER

Taap Water provides affordable, clean and sustainable water solutions straight from the tap at home..

The company is based in London, but also operates in Spain.

It has a team of experienced water and technology experts.

In its last round of Series A funding, earlier this year, it was able to raise $2,1M.

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu